NanoViricides Granted Approval for Phase II Trial of NV-387 for MPox Treatment

NanoViricides, Inc. has received approval from the DRC's regulatory agency ACOREP to commence a Phase II clinical trial of NV-387 for treating MPox. This trial aims to assess the safety and efficacy of NV-387 against hMPXV infections. The approval marks a key milestone in the regulatory journey of NV-387.

No effective treatments for hMPXV infections currently exist. Tecovirimat, another potential treatment, showed no superiority over placebo in trials. NV-387, however, promises a broad-spectrum antiviral solution, targeting a vast range of human pathogenic viruses via biomimicry.

NV-387's broad efficacy was demonstrated across various viruses, including influenza and coronavirus, where it outperformed existing drugs. With community spread of MPox Clade I emerging in the US, the development of NV-387 could be significant in combating viral threats globally.